Colorectal cancer screening by fecal immunochemical test or colonoscopy in France: how many people are actually covered? Focus on the Provence-Alpes-Côte d’Azur region

Background Colorectal cancer (CRC) screening with fecal immunochemical test (FIT) remains low in France, particularly in the Provence-Alpes-Côte-d’Azur (PACA) region. The aim of this study was to compare insured persons (50–74 years) who had FIT and/or colonoscopy in PACA with the general French population. Methods FIT and colonoscopy rates were calculated according to SP-France and National Health Data System data. Results The rate of FIT in 2016–2017 was lower in PACA than in France (25.6 vs. 29.1%, P < 0.001). Conversely, in 2013–2017, the rate of colonoscopy in the past 5 years was higher in PACA than in France (23.1 vs. 20.1%, P < 0.001). Total rate for FIT within 2 years and/or colonoscopy within 5 years was 46.0% in PACA vs. 46.5% in France (P < 0.001). Overuse was higher for diagnostic (1.21) than therapeutic colonoscopies (1.05). Therapeutic colonoscopy occurred more with FIT than without (47.88 vs. 38.7%, P < 0.001). According to USA criteria, persons with FIT within 2 years and/or sigmoidoscopy and/or colonoscopy within 10 years was 59.4% in PACA vs. 54.7% in France (P < 0.001). Conclusion Low participation in FIT in France must be improved to increase the rate of therapeutic colonoscopies and reduce the incidence of CRC. The higher colonoscopy rate in PACA could explain the lower CRC mortality. Efforts should be focused on the more than 40% of French insured who are not screened by either FIT or colonoscopy.

[1]  H. Brenner,et al.  The Effects of Different Invitation Schemes on the Use of Fecal Occult Blood Tests for Colorectal Cancer Screening: Systematic Review of Randomized Controlled Trials , 2021, Cancers.

[2]  H. Leleu,et al.  Cost-effectiveness analysis of alternative colon cancer screening strategies in the context of the French national screening program , 2020, Therapeutic advances in gastroenterology.

[3]  H. Leleu,et al.  [Estimated impact of the current colorectal screening program in France]. , 2020, Revue d'epidemiologie et de sante publique.

[4]  G. Zhong,et al.  Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis. , 2019, Gastrointestinal endoscopy.

[5]  M. Zappa,et al.  Associations between cervical, breast and colorectal cancer screening uptake, chronic diseases and health-related behaviours: Data from the Italian PASSI nationwide surveillance. , 2019, Preventive medicine.

[6]  J. Dillner,et al.  Invitation strategies and coverage in the population-based cancer screening programmes in the European Union , 2019, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[7]  Christopher D. Jensen,et al.  Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. , 2018, Gastroenterology.

[8]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[9]  C. Flowers,et al.  Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society , 2018, CA: a cancer journal for clinicians.

[10]  M. Kaminski,et al.  Adenoma detection rate and risk of colorectal cancer. , 2017, Best practice & research. Clinical gastroenterology.

[11]  Ihssen Belhadj,et al.  Data Resource Profile: The French National Uniform Hospital Discharge Data Set Database (PMSI). , 2017, International journal of epidemiology.

[12]  I. Gendre,et al.  Bilan des 18 premiers mois du programme français de dépistage du cancer colorectal par test immunologique , 2017 .

[13]  E. Kuipers,et al.  Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels. , 2017, Gastroenterology.

[14]  J. Faivre,et al.  Additional mailing phase for FIT after a medical offer phase: The best way to improve compliance with colorectal cancer screening in France. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[15]  Á. Lanas,et al.  Correlation between adenoma detection rate in colonoscopy- and fecal immunochemical testing-based colorectal cancer screening programs , 2017, United European gastroenterology journal.

[16]  J. Saurin.  Screening for colorectal cancer in France: How to improve adhesion and participation? , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[17]  W. Cheung,et al.  Correlation between County-Level Surgeon Density and Mortality from Colorectal Cancer , 2016, Journal of Gastrointestinal Cancer.

[18]  Liang-hao Hu,et al.  Colonoscopy Reduces Colorectal Cancer Incidence and Mortality in Patients With Non-Malignant Findings: A Meta-Analysis , 2016, The American Journal of Gastroenterology.

[19]  M. Zappa,et al.  Impact of Screening Program on Incidence of Colorectal Cancer: A Cohort Study in Italy , 2015, The American Journal of Gastroenterology.

[20]  M. Zorzi,et al.  Screening for colorectal cancer in Italy: 2011-2012 survey. , 2015, Epidemiologia e prevenzione.

[21]  A. Jemal,et al.  Public Health Impact of Achieving 80% Colorectal Cancer Screening Rates in the United States by 2018 , 2015, Cancer.

[22]  H. Brenner,et al.  Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies , 2014, BMJ : British Medical Journal.

[23]  Aasma Shaukat,et al.  Long-term mortality after screening for colorectal cancer. , 2013, The New England journal of medicine.

[24]  Mark P Purdue,et al.  Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. , 2012, The New England journal of medicine.

[25]  A. G. Gimeno García,et al.  Factors Influencing Colorectal Cancer Screening Participation , 2011, Gastroenterology research and practice.

[26]  L. Bisanti,et al.  Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. , 2011, Journal of the National Cancer Institute.

[27]  A. Ananthakrishnan,et al.  Higher Physician Density is Associated with Lower Incidence of Late-stage Colorectal Cancer , 2010, Journal of General Internal Medicine.

[28]  Cancer,et al.  Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial , 2010, The Lancet.

[29]  V. Bouvier,et al.  Socioeconomic determinants for compliance to colorectal cancer screening. A multilevel analysis , 2009, Journal of Epidemiology & Community Health.

[30]  M. Bretthauer,et al.  Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial , 2009, BMJ : British Medical Journal.

[31]  J. Habbema,et al.  Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels , 2009, British Journal of Cancer.

[32]  F. Chan,et al.  Asia Pacific consensus recommendations for colorectal cancer screening , 2008, Gut.

[33]  A. Verbeek,et al.  Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. , 2008, Gastroenterology.

[34]  B. Levin,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. , 2008, Gastroenterology.

[35]  J. Faivre,et al.  Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. , 2004, Gastroenterology.

[36]  O. Kronborg,et al.  Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds , 2004, Scandinavian journal of gastroenterology.

[37]  J. Faivre,et al.  European Commission's proposal for a council recommendation on cancer screening , 2003, BMJ : British Medical Journal.

[38]  S. Moss,et al.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer , 1989, The Lancet.

[39]  Colorectal Cancer Screening in Average-Risk Adults , 2019, Annals of Internal Medicine.

[40]  M. Zorzi,et al.  Screening for colorectal cancer in Italy: 2011-2012 survey. , 2015, Epidemiologia e prevenzione.

[41]  E. Paci,et al.  The impact of immunochemical faecal occult blood testing on colorectal cancer incidence. , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.